AUS
NZ
UK
CA
USA
IND
Highlights
- Radiopharm has received firm commitments from investors, including Lantheus Holdings, Inc. (Lantheus), to raise approximately AUD 35.0 million through a placement.
- Placement subscribers are anticipated to receive one free attaching option for every placement share subscribed at an exercise price of AUD 0.039.
- Following the placement, Radiopharm intends to offer a Share Purchase Plan (SPP) to raise up to AUD 5 million for existing eligible shareholders in Australia and New Zealand.
- Radiopharm’s clinical programs revealed encouraging early data across RAD 101, RAD 202, RAD 204, and RAD 301, with multiple trials progressing toward key milestones in 2025–2026.
- The company looks forward to initiating Phase 1 trials for RV01 and RAD402, its promising preclinical monoclonal antibody assets, by year-end.
Radiopharm Theranostics Limited (ASX:RAD; NASDAQ:RADX), a developer of radiopharmaceutical products for diagnostic and therapeutic applications, has received firm commitments from international and Australian institutional and industry investors, including Lantheus Holdings, Inc. The company will raise approximately AUD 35.0 million through a placement of about 1,167 million new fully paid ordinary shares at AUD 0.03 per share.
Following the placement, Radiopharm intends to offer a Share Purchase Plan (SPP) to raise up to AUD 5 million from the existing eligible shareholders in Australia and New Zealand. Applications under the SPP are capped at AUD 30,000 per shareholder and will be made on the same terms as the placement. Attaching options issued under the SPP will also be subject to shareholder approval.
In another update, Radiopharm today provided details on its pipeline of clinical programs and outlined expected milestones through the end of 2025 and into 2026.
“We are highly encouraged by the consistent and positive data emerging from our four lead clinical programs, which continue to validate the potential of our differentiated radiopharmaceutical pipeline. Our strategic execution remains strong, and we anticipate a steady stream of topline data readouts across multiple trials in the near term. As we advance these programs toward their next stages of development, we are proud of the meaningful progress being made. On behalf of our entire team, I express our gratitude to the investigators, patients, and families participating in our clinical trials, their trust and commitment are the foundation of our work,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics.
Shares of RAD traded at AUD 0.029 at the time of writing on 20 October 2025.
